國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Induction of mucosal immunity using ...

Hunter, Zoe.

Induction of mucosal immunity using virus-like particle based vaccines.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Induction of mucosal immunity using virus-like particle based vaccines.
作者:	Hunter, Zoe.
面頁冊數:	144 p.
附註:	Source: Dissertation Abstracts International, Volume: 72-10, Section: B, page: .
附註:	Adviser: Bryce Chackerian.
Contained By:	Dissertation Abstracts International72-10B.
標題:	Biology, Molecular.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3460982
ISBN:	9781124739519

Induction of mucosal immunity using virus-like particle based vaccines.
Hunter, Zoe.

Induction of mucosal immunity using virus-like particle based vaccines. - 144 p.

Source: Dissertation Abstracts International, Volume: 72-10, Section: B, page: .

Thesis (Ph.D.)--The University of New Mexico, 2011.

Many viral structural proteins are capable of spontaneously self-assembling into structures that resemble virus particles. These structures, called virus-like particles (VLPs), have multivalent, highly repetitive structures which are capable of inducing robust and enduring immune responses, and, therefore, can serve as the basis for effective vaccines. VLPs can be used as stand-alone vaccines targeting the viruses from which they are derived and also as platforms for presenting heterologous antigens; their ability to evoke strong antibody responses against even poorly immunogenic targets makes them an attractive model for future vaccine and drug delivery vehicle designs. Our lab developed display technologies that allow us to modify VLPs so they can present essentially any potential target antigen on its surface. These technologies have led to the development of several VLP-based vaccines that target molecules derived from microbial and self-antigens. We have previously shown that when given intramuscularly, these vaccines consistently induce high-titer serum antibodies. Here we present data showing that VLP-based vaccines are compatible with mucosal deliveries to both the genital and respiratory tracts. Specifically, we displayed peptides from the HPV16 L2 coat protein on the bacteriophage VLP platform PP7, and used a second bacteriophage VLP platform, Q!, to target two domains of the cellular HIV coreceptor CCR5 involved in HIV binding. Vaccines targeting both the viral and self-antigens were successful at inducing mucosal and systemic immune responses, represented by the presence of IgA- and IgG-specific antibodies. The induction of both mucosal and systemic immune responses presents a particular advantage for preventing infection by pathogens transmitted at mucosal surfaces. Indeed, we determined that the L2 mucosal vaccine was successful at preventing genital pseudoviral infection in a mouse model of HPV infection. As a demonstration of the VLP's ability to evoke strong antibody responses against a self - and therefore weakly immunogenic - molecule, we also present data indicating that immunization of macaques with our CCR5 vaccine results in the maintenance of undetectable viral loads in some animals, indicating protection from infection following a high-dose challenge with SIV. Our results provide a general method for the induction of a broad, comprehensive immune response using VLPs as vaccine platforms.

ISBN: 9781124739519Subjects--Topical Terms:

226919
Biology, Molecular.

Induction of mucosal immunity using virus-like particle based vaccines.
LDR:03514nmm 2200325 4500 001 309769
005 20111105132512.5
008 111212s2011 ||||||||||||||||| ||eng d
020 $a 9781124739519
035 $a (UMI)AAI3460982
035 $a AAI3460982
040 $a UMI $c UMI
100 1 $a Hunter, Zoe. $3 531138
245 1 0 $a Induction of mucosal immunity using virus-like particle based vaccines.
300 $a 144 p.
500 $a Source: Dissertation Abstracts International, Volume: 72-10, Section: B, page: .
500 $a Adviser: Bryce Chackerian.
502 $a Thesis (Ph.D.)--The University of New Mexico, 2011.
520 $a Many viral structural proteins are capable of spontaneously self-assembling into structures that resemble virus particles. These structures, called virus-like particles (VLPs), have multivalent, highly repetitive structures which are capable of inducing robust and enduring immune responses, and, therefore, can serve as the basis for effective vaccines. VLPs can be used as stand-alone vaccines targeting the viruses from which they are derived and also as platforms for presenting heterologous antigens; their ability to evoke strong antibody responses against even poorly immunogenic targets makes them an attractive model for future vaccine and drug delivery vehicle designs. Our lab developed display technologies that allow us to modify VLPs so they can present essentially any potential target antigen on its surface. These technologies have led to the development of several VLP-based vaccines that target molecules derived from microbial and self-antigens. We have previously shown that when given intramuscularly, these vaccines consistently induce high-titer serum antibodies. Here we present data showing that VLP-based vaccines are compatible with mucosal deliveries to both the genital and respiratory tracts. Specifically, we displayed peptides from the HPV16 L2 coat protein on the bacteriophage VLP platform PP7, and used a second bacteriophage VLP platform, Q!, to target two domains of the cellular HIV coreceptor CCR5 involved in HIV binding. Vaccines targeting both the viral and self-antigens were successful at inducing mucosal and systemic immune responses, represented by the presence of IgA- and IgG-specific antibodies. The induction of both mucosal and systemic immune responses presents a particular advantage for preventing infection by pathogens transmitted at mucosal surfaces. Indeed, we determined that the L2 mucosal vaccine was successful at preventing genital pseudoviral infection in a mouse model of HPV infection. As a demonstration of the VLP's ability to evoke strong antibody responses against a self - and therefore weakly immunogenic - molecule, we also present data indicating that immunization of macaques with our CCR5 vaccine results in the maintenance of undetectable viral loads in some animals, indicating protection from infection following a high-dose challenge with SIV. Our results provide a general method for the induction of a broad, comprehensive immune response using VLPs as vaccine platforms.
590 $a School code: 0142.
650 4 $a Biology, Molecular. $3 226919
650 4 $a Health Sciences, General. $3 212650
650 4 $a Health Sciences, Immunology. $3 226966
690 $a 0307
690 $a 0566
690 $a 0982
710 2 $a The University of New Mexico. $b Biomedical Sciences. $3 531139
773 0 $t Dissertation Abstracts International $g 72-10B.
790 1 0 $a Chackerian, Bryce, $e advisor
790 1 0 $a Ozbun, Michelle $e committee member
790 1 0 $a Prossnitz, Eric $e committee member
790 1 0 $a Rubin, Robert L. $e committee member
790 $a 0142
791 $a Ph.D.
792 $a 2011
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3460982